We describe a phage display approach that we have previously used to generate conformation-sensor antibodies that specifically recognize and stabilize the oxidized, inactive conformation of protein tyrosine phosphatase 1B (ptp1B). We use a solutionbased panning and screening strategy conducted in the presence of reduced active ptp1B, which enriches antibodies to epitopes unique to the oxidized form while excluding antibodies that recognize epitopes common to oxidized and reduced forms of ptp1B. this strategy avoids conventional solid-phase immobilization owing to its inherent potential for denaturation of the antigen. In addition, a functional screening strategy selects single-chain variable fragments (scFvs) directly for their capacity for both specific binding and stabilization of the target enzyme in its inactive conformation. these conformation-specific scFvs illustrate that stabilization of oxidized ptp1B is an effective strategy to inhibit ptp1B function; it is possible that this approach may be applicable to the protein tyrosine phosphatase (ptp) family as a whole. With this protocol, isolation and characterization of specific scFvs from immune responsive animals should take ~6 weeks.
IntroDuctIon
The term antibody phage display library refers to a collection of phage particles that display recombinant antibody fragments fused to surface proteins [1] [2] [3] [4] [5] . Antibody phage display is a powerful and effective technique for the generation and selection of specific antibodies from a large and diverse collection of functional antibodies in the library 6 . Antibody fragment-expressing genes can be produced from a naive source 7 or derived after immunization 2 , or they can be produced by introducing random mutations in vitro in one or more complementarity determining regions (CDRs) 3 . Recombinant antibodies presented at the surface of bacteriophages can be selected from combinatorial libraries under extensively controlled conditions 8, 9 . This in vitro process allows selection of antibodies to highly conserved antigens. In comparison with traditional approaches for generating antibodies from animals, this has the major advantage of preserving the natural conformation of the antigen of interest to allow the generation of conformation-specific antibodies by successive rounds of selection or panning 10, 11 . Among several different methods for selecting antibody fragments, including ribosomal, bacterial or yeast display, antibody phage display has proven to be a robust, versatile and extensively applied method 12 .
For selection of antibodies for a target antigen, two functional antigen-binding fragments, designated Fab and scFv, can be displayed on the phage 11 . The Fab (fragment antigen-binding) fragment is composed of one constant and one variable domain of each of the heavy and light chains, whereas the smaller Fv (fragment variable) is composed of the variable light (V L ) and variable heavy (V H ) regions. A scFv is generated by joining the two variable regions with a flexible peptide linker ( Fig. 1 ) and expressed as a recombinant polypeptide chain fused to the surface protein of phage particles 13 . These scFvs can be expressed as single polypeptides, which retain the binding specificity of functional antibodies. The use of scFvs offers several advantages over the use of Fab fragments. The smaller insert size in scFv libraries renders them relatively more stable than Fab libraries 14 . Fab fragments are twice the size of scFvs and require more extensive assembly and folding in the bacterial expression system 15 . Moreover, scFv expression generally has a less toxic effect on the bacteria than expression of larger Fab fragments. As a result, functional scFvs are produced in a higher yield in Escherichia coli 5 . Generation and screening of specific functional antibodies using scFv libraries also offers practical benefits. The use of short, single-chain fragments makes the construction of a large and diverse library easier 15 . It is also more convenient to generate higher-affinity mutants of scFv by site-directed mutagenesis or antibody engineering 16 . One of the major advantages of using this approach is that the candidate antibodies can be expressed inside mammalian cells as functional intracellular antibodies or 'intrabodies' [17] [18] [19] [20] [21] [22] [23] [24] [25] , and used as probes for the function and posttranslational modification of intracellular targets. This protocol was originally developed to produce scFvs that selectively recognize the oxidized conformation of the protein tyrosine phosphatase PTP1B, which is generated in vivo in a wide variety of signaling contexts, and to test their potential as tools to modify the signaling function of the enzyme 26 .
PTP1B is the prototypic member of the PTP family 27 and has a pivotal role in regulating insulin and leptin signaling 28, 29 . PTP1B contains a signature catalytic motif (the PTP loop), [ 30 . Cys215 and Arg221 within this motif are indispensable for phosphatase activity 30 . On the basis of its important role in regulating insulin and leptin signaling, considerable interest has grown in harnessing PTP1B as a therapeutic target, particularly for the treatment of diabetes and obesity 31, 32 . The highly charged catalytic core of the reduced active form of PTP1B, however, has been a major obstacle to developing active site-directed inhibitors of this enzyme that have appropriate drug development potential. Moreover, selectivity of inhibitors over closely related PTPs has been a challenge because of the highly conserved nature of the active site across the PTP family. For example, the catalytic domain of the T cell protein tyrosine phosphatase (TCPTP) shows ~75% sequence identity to PTP1B, and the tertiary structures of these two enzymes overlap closely 33, 34 ; in fact, most of the potent catalytic site-directed PTP1B inhibitors also show some degree of inhibition of TCPTP activity 35 . Consequently, novel approaches are required to generate inhibitors of the PTP family that would be acceptable for drug development.
I/V]HCXAGXXR[S/T]G, which is conserved among all PTPs
PTPs are oxidized and inactivated by reactive oxygen species produced in response to a variety of physiological stimuli, including insulin [36] [37] [38] [39] . Analysis by X-ray crystallography has revealed that mild oxidation of the active site cysteine of PTP1B generates a 5-atom cyclic sulfenyl amide species, in which the sulfur atom of the active site cysteine is covalently linked to the main-chain nitrogen of the adjacent serine residue 40, 41 . In this reversibly oxidized form (PTP1B-OX), elements of the catalytic cleft of PTP1B, including the PTP loop and Tyr46 of the pTyr loop, are presented on the protein surface ( Fig. 1) , which inhibits substrate binding and renders the enzyme inactive. The profound conformational change at the active site that is induced by reversible oxidation presents new, unique binding surfaces. If this transiently oxidized form of PTP1B can be stabilized, locking the enzyme in an inactive conformation, then this may provide an alternative approach to manipulate the function of the enzyme under pathophysiological conditions. Our goal was to test this hypothesis by generating scFvs directed against oxidation-specific epitopes of PTP1B, which could be expressed in cells as intrabodies that would stabilize the oxidized conformation of PTP1B, thereby inhibiting its phosphatase function and promoting insulin signaling 26 . This approach of inhibiting PTPs through stabilization of the inactive, oxidized conformation may represent a new way of inhibiting other redox-sensitive PTPs selectively for pathophysiological intervention.
The isolation of specific antibodies against the oxidized conformation of PTP1B would be difficult by conventional antibody production techniques. Phage display allows an easy and flexible process for the selection of specific antibodies to defined epitopes presented on isolated, purified antigens. In most cases, the antigen of interest is presented to the antibody phage library on solid surfaces as an immobilized bait; however, immobilization limits the enrichment and selection of conformation-specific antibodies, because the conformation of the epitope can be compromised, or improperly exposed 42 . An appropriate panning and screening method, which preserves a specific conformation of the antigen in conditions under which the epitope is properly presented without structural alteration, is the main prerequisite for a successful selection strategy. Nizak et al. 21 reported the generation of scFvs specific to the GTP-bound form of the GTPase Rab6 by performing selections against a GTP-locked mutant. Covalent modification with a small-molecule inhibitor, to lock the target antigen in a particular conformation for selection purposes, has also been reported 43 . Eisenhardt et al. 44 described a subtractive panning strategy to select conformation-specific antibodies against cell surface targets. PTP1B, however, is a tail-anchored protein in which the C terminus targets the protein to the endoplasmic reticulum membrane with the catalytic domain exposed to the cytoplasm 45 . Furthermore, endogenous PTP1B undergoes various degrees of oxidation, depending on signaling cues. Consequently, screening by targeting endogenous PTP1B directly is difficult. Therefore, we designed a solution-based, in vitro selection strategy and a subsequent enzyme activity-based screening method that were crucial for preserving specific interactions between the candidate scFvs and a particular conformation of the antigen. We used this in vitro technique with several empirically optimized modifications to enrich and isolate candidate scFvs to PTP1B-OX systematically 26 .
A major challenge to producing antibodies that are selective for particular conformations of a protein is to have homogenous preparations of the target antigen displaying that particular conformation in a stable manner. The crystal structures of the doubly mutated form of PTP1B (PTP1B-C215A/S216A, termed PTP1B-CASA) and the reversibly oxidized form are identical 26 . Consequently, this PTP1B-CASA mutant captures the conformation of the oxidized enzyme in a stable manner, generating a homogeneous preparation of the antigen. The solution-based panning strategy, carried out in the presence of up to 50-fold molar excess of the reduced, wild-type enzyme, ensured that antibodies recognizing specific epitopes on PTP1B-OX were enriched, whereas those that bound common epitopes on both conformations of the protein were depleted. To enrich specific scFvs from the phage display library, we used biotinylated PTP1B-CASA and streptavidin bead capture. Although similar approaches have been reported previously for isolating scFvs 21, 46, 47 , we adopted an in vivo biotinylation method (Box 1). We fused a sequence motif to the N terminus of the target antigen (PTP1B-CASA), which allowed the addition of a biotin moiety specifically to a single lysine residue found only in the tag, leaving the rest of the protein unmodified 48 . This was important because biotinylation of PTP1B by this method did not 40, 41 . Tyr46 of the pTyr loop, which defines the depth of the catalytic cleft, and the PTP loop containing the signature catalytic motif, which is located at the base of the cleft under reducing conditions, both adopt a solvent-exposed position (shown in yellow) in the oxidized state. In PTP1B-CASA, mutation of both the catalytic Cys215 and Ser216 to alanine breaks the same hydrogen bonds that are disrupted by oxidation of the active site cysteine, which induces a conformation that is identical to that of the oxidized enzyme 26 alter enzyme activity, whereas modification by chemical biotinylation was inhibitory. This suggests that the specific addition of biotin to the N-terminal tag did not cause any unwanted structural change in PTP1B, and that oxidation-specific epitope(s) in the biotinylated PTP1B-CASA protein were preserved.
This protocol provides a thorough, step-by-step description of the panning and screening strategies for isolating scFvs that bind specifically to the oxidized conformation of PTP1B. We selected specific scFvs using an in-solution screen that exploited an in vitro phosphatase assay (Box 2) to measure reactivation of PTP1B-OX that had been reversibly oxidized by H 2 O 2 in vitro. Through our screening method, we isolated scFvs that not only bound to PTP1B-OX but also stabilized the inactive conformation and inhibited its reactivation by a reducing agent. This novel approach to the inhibition of PTP1B function suggests that small molecules that mimic the stabilizing effects of the scFvs may have therapeutic potential. Oxidation of PTPs is emerging as a regulatory mechanism for many different cellular pathways 49 . In addition to PTP1B, specific examples include the oxidation of SHP2 in PDGF signaling 36 , TCPTP in insulin signaling 39 and multiple PTPs in B-cell receptor signaling 50, 51 . In addition, the oxidation of several receptor PTPs, including PTP-α and LAR 52 , dual-specificity PTPs (e.g., PTEN and MKP-1) [52] [53] [54] , has been reported. In fact, a similar cyclic sulfenyl amide modification has been observed in the active site of oxidized PTP-α 55 . Considering the key regulatory roles of these PTPs, the development of conformation-sensor antibodies that can recognize and stabilize the oxidized inactive forms of these enzymes will generate important tools with which to investigate the regulation of cell signaling. The activity of many other biologically important regulatory proteins also depends on conformational switches 36, 56, 57 .
Overall, our protocol describes an approach that not only applies to the PTP family as a whole, but also may represent a general scheme for selecting and testing the ability of scFvs to recognize and stabilize biologically relevant protein conformers so as to alter a particular biological function or pathway.
experImental DesIgn
Construction of the antibody phage display library. Particular attention should be paid to antigen preparation. It is very important to generate a preparation in which the required conformation is adopted in a stable manner. In our case, this was facilitated by detailed structural analysis, which revealed that the PTP1B-CASA double mutant was locked in the same conformation as oxidized PTP1B. This understanding of the structural consequences of oxidation was a key element of success. We expressed the 37-kDa form of wild-type PTP1B or the PTP1B-CASA mutant (comprising residues 1-321 without any epitope tag) in E. coli and purified it to homogeneity by following a previously described method 58 . This form of PTP1B comprises the catalytic domain; however, in the cell the native enzyme is expressed as a longer protein with a noncatalytic C-terminal segment that is challenging to express in homogeneous form owing to sensitivity to proteolysis. This detailed understanding of the properties of the target antigen permitted us to focus on a form of the enzyme that is stable, readily purified and preserves the important conformational changes we wished to study.
In our case, we generated a phage display library displaying scFvs fused to phage surface protein pIII from immune genes collected from spleen and bone marrow of chickens immunized with PTP1B-CASA. However, scFv libraries can also be
Box 1 | Biotinylation of PTP1B • tImIng ~2 weeks including cloning, expression and purification
We expressed PTP1B with an N-terminal biotinylation sequence from a pET19b vector in E. coli [BL21(DE3)], together with the pBirAcm plasmid that harbors recombinant biotin ligase. 1. By using standard cloning strategies, PCR-amplify the catalytic domain (residues 1-321) of the WT or CASA mutant with the biotinylation tag with an additional NcoI restriction site at the 5′ end of the tag and clone in pET19b plasmid to make the expression construct for NBT-PTP1B (N-terminally biotinylated PTP1B). The primers used for this amplification are: 5′-GGGGAACCATGGGCCTGAA CGACATCTTCGAGGCTCAGAAAATCGAATGGCACGAAATGGAGATGGAAAAGGAGTTCG-3′ (sense) and 5′-AGCAGCCGGATCCCCCGGGCTGCAGGAATTCTCTAG ACTAGAG-3′ (antisense). 2. By using standard methods, transform competent BL21(DE3) cells with the recombinant biotin ligase (BirA)-containing plasmid pBirAcm and maintain under the selection of chloramphenicol (10 µg ml − 1 ) on LB agar plates. 3. Make pBirAcm-containing bacteria (from step 2) chemically competent, again using standard methods, and transform them with the NBT-PTP1B constructs from step 1. Maintain the doubly transformed cells under the selection of both chloramphenicol (10 µg ml − 1 ) and ampicillin (100 µg ml − 1 ) on LB agar plates. 4. Induce the expression of recombinant proteins with 1 mM IPTG in the presence of 50 µM biotin in the growth medium for 4 h at 37 °C. 5. In the first step of purification, separate the biotinylated recombinant protein by immobilized monomeric avidin and elute with 5 mM biotin in PBS according to the manufacturer's instructions. 6. In the second step, further purify the protein by HiTrap Q FF anion exchange chromatography using a standard FPLC protocol and following the manufacturer's instructions. Elute the protein in Q-buffer B. Dialyze the protein in PTP1B storage buffer overnight at 4 °C. 7. To ensure efficient recovery of the antigen under the panning conditions and to assess the efficiency of the biotinylation in vivo, check NBT-CASA or NBT-WT in a streptavidin pull-down experiment (steps 8 and 9). 8. Mix the biotinylated proteins (10 nM final) with 25 µl of streptavidin-coated magnetic beads in 1 ml of TBS containing 2% (wt/vol) BSA, 5 mM DTT, 0.5% (vol/vol) Tween-20 and 0.02% (wt/vol) NaN 3 and incubate with gentle rotation at 4 °C for 2 h. 9. Wash the beads three times with cold TBS (2% (wt/vol) BSA, 5 mM DTT, 0.5% (vol/vol) Tween-20 and 0.02% (wt/vol) NaN 3 ) and separate the proteins by SDS-PAGE. Detect PTP1B by blotting with anti-PTP1B antibody (FG6) and the biotinylated protein with anti-biotin-HRP antibody.
produced from a naive source 7 , or they can be produced by introducing random mutations in vitro in one or more CDRs 3. The generation of antibody phage display libraries from animals already immunized with the antigen is advantageous because diversity of the antibodies for the antigen is already created in vivo by the immune system 2, 59 . Many antigens of mammalian origin are not present or less conserved in avian species, such as chickens, which are a useful source for producing a large number of immune genes against the antigen of interest. In addition, chickens generally produce an increased immune response compared with mice and rabbits 60, 61 . Detailed protocols for the construction of an scFv library from immunized chickens can be found in refs. 60,62. A diverse library is an important prerequisite for successful isolation of specific scFvs. We constructed two different types of scFvs, one with a short linker sequence (GQSSRSS) and one that was longer (GQSSRSSSSGGGGSGGGG), and mixed them together to add diversity to the library. Diversity can be further increased during the generation of scFvs, by varying the order of the variable domains at either the N terminus or at the C terminus 13, 63 or by changing the length of the polypeptide linker between the two variable domains 64 . Linkers having different lengths may lead to different degrees of oligomerization of the generated scFvs. Reports have shown that scFvs with the shorter linkers tend to form dimers as compared with the longer linkers, which tend to form monomers 65 . After the panning steps, we mostly observed the enrichment of scFvs with the shorter linker. We found only one clone with the longer linker, but when purified as a soluble scFv from bacteria it did not have any binding or stabilizing effect on PTP1B-OX.
Combining replicates of the PCR amplification and ligation reactions during the construction of the library can improve the scFv diversity. In addition, to maintain the initial diversity of the library, large volumes of culture can be used to inoculate a large number of infected cells during the selection process. One concern about maintaining the original diversity of the library is that each round of amplification can result in a reduction of diversity in the scFv repertoire because of potential outgrowth of fast-growing clones. It is therefore important to use a library that has been freshly amplified from the original library before starting the selection process. Libraries that have undergone several rounds of amplification should be reassessed for the presence of full-length scFv inserts by sequencing randomly picked clones.
Expression and purification of in vivo biotinylated PTP1B.
When using the antigen of interest in the in-solution panning (Steps [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , it is essential to purify the biotinylated target antigen in homogeneity (Box 1 and Fig. 2 ) Recombinant PTP1B can be readily expressed in BL21 E. coli; therefore, we used this expression system to coexpress PTP1B and biotin ligase. If another bacterial system was to be used, the conditions for coexpression of both proteins, biotinylation efficiency and purification steps would have to be optimized accordingly. Initially, we used a chemical biotinylation approach, in which we added biotin moieties to free amines nonspecifically. This method caused marked inhibition of PTP1B activity, probably by modifying the chemical and structural integrity of the active site or other important sites required for activity. To isolate conformation-specific scFvs, it is important to avoid modifications that may affect structural integrity. Therefore, we adopted an in vivo approach to biotinylate PTP1B-CASA specifically using a biotinylation tag fused to the N terminus of the protein. Biotin ligase specifically recognizes this 15-residue peptide tag (GLNDIFEAQKIEWHE), and in the presence of ATP attaches biotin to the lysine residue in this sequence 48 . The pBirAcm plasmid, which was isolated from DNase-deficient K-12 E. coli strain (AVB99, Avidity), is an engineered pACYC184 plasmid (ColEI compatible) that harbors an IPTG-inducible birA gene to overexpress biotin ligase, which adds biotin specifically to the lysine residue in the biotinylation tag. The addition of biotin to the growth medium during the time of induction ensures the biotinylation of the tagged protein. If in vivo biotinylation of the target antigen is difficult, one can biotinylate the target antigen specifically by purifying the protein with the biotinylation tag and then using commercially available biotin ligase (Avidity) to add biotin in vitro.
In-solution panning (Steps 1-20).
Panning or selection of specific scFvs can be performed in several ways. Immobilization of the antigen on a solid surface is perhaps most common; however, other methods such as the use of whole cells, tissue sections and in vivo panning have been reported 66 . Immobilization causes random attachment of the antigen onto the plastic surface without any uniform directional orientation and may lead to partial Box 2 | Phosphatase assay to determine the activity of PTP1B • tImIng ~2 d including substrate preparation and enzymatic assay RCML was used as a substrate in a phosphatase assay 53, 54 for activity-based screening for PTP1B-OX conformation-sensor scFvs. Other substrates of PTP1B could also be used in the assay. 1. Phosphorylate RCML with 32 P using recombinant GST-FER kinase and [γ 32 P] ATP to stoichiometry of ~0.8 mol 32 P incorporated per mol of protein, as described in ref. 55 . 2. Mix PTP1B (1-321)-WT without any modification and PTP1B (1-321)-WT or CASA with N-terminal biotinylation in vivo in E. coli (5 nM PTP1B final concentration) with 500 nM 32 P-RCML in phosphatase assay buffer (50 mM HEPES (pH 7.0), 100 mM NaCl, 0.1% (wt/vol) BSA and 5 mM TCEP) and incubate at 30 °C for 10 min. 3. Stop the reaction with 10% (vol/vol) TCA (final) with 2.5% (wt/vol) BSA and incubate at − 80 °C for 30 min. 4. Thaw the reaction at room temperature, spin at top speed in a microcentrifuge for 5 min and collect an aliquot of the supernatant. 5. Determine the release of 32 P-phosphate by scintillation counting. Compare the specific activity of the protein preparations with that of the untagged PTP1B (1-321), the activity of which was set as 100%. ? trouBlesHootIng denaturation 42 ; consequently, the conformational difference at the active site between the reduced and oxidized form of proteins may not be preserved under these conditions. In some protocols, the antigen is attached to the plastic by initially treating the surface with a high-pH coating buffer. This elevated pH may also cause denaturation of the protein, resulting in improper presentation of the conformational epitope(s) of interest.
In our protocol, selection of specific scFvs is performed in solution, without structural alteration of the target antigen due to chemical modification or immobilization. Biotinylation of PTP1B-CASA on an N-terminal tag did not cause nonspecific modification in the catalytic domain of the enzyme and did not affect the function of the wild-type enzyme or its reactivation status after oxidation. Maintaining the structural integrity of the tagged antigen throughout the panning steps is important to permit isolation of the conformation-sensor scFvs from solution. Furthermore, we modified this solution-based panning by simultaneous addition of a molar excess of reduced active enzyme (PTP1B-WT) together with the biotinylated target antigen (PTP1B-CASA) to enrich for scFvs that are specific to the oxidized conformation. Wild-type PTP1B should be stored in the presence of a reducing agent to avoid oxidation and inactivation in the storage buffer. Repeated freezethaw cycles should also be avoided for both the wild-type and mutant proteins. From this in-solution mixture, we captured scFvdisplaying phage particles bound to the biotinylated antigen (CASA mutant) using streptavidin-coated magnetic beads. We applied amplified phages from the first round of selection in the second round of panning, and we repeated this process for five rounds of panning under similar selection conditions. Complete in-solution panning comprises phage preadsorption, addition of both reduced wild-type PTP1B and the biotinylated CASA mutant, capture of the scFv-phage-antigen complex with SA-coated magnetic beads, elution of the phage particles and phage amplification (Fig. 3) . We used acidic buffer conditions to elute the scFv-expressing phage particles from the antigen-phage (scFv)-magnetic bead complex. By changing the mode of elution (acid vs. base), different subsets of scFv population may be obtained and characterized.
In any selection, special procedures should be designed to minimize the enrichment of nonspecific sequences. The binding buffer should be supplemented with BSA to reduce nonspecific binding of scFvs to the magnetic beads and the plastic surface of the tubes. Appropriate wash steps are important for efficient enrichment of the specific scFvs. If the washes are too stringent, they may remove not only nonspecific scFvs but also specific scFvs with low affinity to the target. The number of panning steps is a vital factor for selection and enrichment of specific scFvs. This can be determined Phosphatase activity of recombinant PTP1B (1-321), which was biotinylated in vivo (NBT-1B-WT or NBT-1B-CASA) or in vitro (1B-WT + BT), was measured using 32 P-RCML as the substrate. The activity of the different PTP1B preparations was compared with that of the untagged wild-type enzyme (1B-WT), which was set as 100%. Error bars represent s.d. from four separate phosphatase assays. (b) The biotinylation sequence is a 15-residue unique peptide, which is recognized by biotin ligase. The biotinylation tag was fused to the N terminus of PTP1B in pET19b vector and coexpressed in E. coli with the recombinant biotin ligase (BirA) by IPTG induction. In the presence of ATP, the ligase specifically attaches biotin to the lysine residue in this tag, which enables homogenous, site-specific in vivo biotinylation 48 . Addition of biotin during the time of induction ensures biotinylation of the tagged protein.
(c-e) Purification of biotinylated PTP1B (1-321, WT and CASA). (c) In the first step, the biotinylated recombinant protein was enriched on monomeric avidin beads and eluted (with 5 mM biotin) fractions were collected. For PTP1B-WT, the corresponding protein fractions demonstrated phosphatase activity as measured by dephosphorylation of the low-Mr substrate pNPP, whereas, as expected, the fractions for the CASA mutant showed no activity. (d) In the second step, the protein was further purified on a Q anion exchange column and eluted with a NaCl gradient. (e) Purified biotinylated proteins were analyzed by SDS-PAGE and Coomassie blue staining. The arrows indicate the migration of the PTP1B protein. (f) The efficiency of biotinylation and the recovery of the biotinylated protein from solution by streptavidin-coated magnetic beads were tested under experimental conditions similar to those used in the in-solution panning steps for enrichment from the antibody phage display library. NBT-1B-CASA (10 nM) was captured with streptavidin-coated magnetic beads and the presence of biotinylated protein (and PTP1B) was detected in input (Inp), supernatant (Sup) and precipitated (Ppt) samples by immunoblotting using antibiotin-HRP and anti-PTP1B antibodies. In the last three lanes (Inp, Sup and Ppt of NBT-1B-CASA), four times more samples were used to increase the load for better detection of the biotinylated proteins.
empirically; in most procedures, three or four rounds of panning are carried out, and then the sequence of the output scFv can be verified to determine the enrichment of the library. The frequency of unique scFvs present after each panning step provides an indication of diversity and enrichment.
Validation of the library quality and the in-solution panning.
After each round of panning, scFvs should be sequenced for quality control analysis of the library and to validate the progress of the panning experiment by assessing the initial diversity and subsequent enrichment of specific scFvs. It is important to verify that the scFv inserts are antibody fragments derived from the species of interest. It must be ensured that full-length scFvs are present in the library without unwanted cloning errors, such as deletion, premature stop codons or no insert at all. Alternatively, scFv sequence variations can be verified by rapid and inexpensive analysis of the restriction digestion patterns by BstO1 endonuclease and agarose gel electrophoresis. This method, however, is limited by the resolving power of the agarose gel.
In-solution functional screening. The yield of purified scFvs depends on expression system, purification conditions and the variable region of the individual scFv. The expression level for phagemid (i.e., pComb3XSS) is generally high enough for using the purified scFvs for direct screening. If required, higher scFv yields can be obtained through subcloning into T7-based vectors (i.e., the pET expression vectors from Novagen) along with BL21(DE3) expression system 67 . Some scFvs may demonstrate increased aggregation or precipitation and formation of inclusion bodies, and this can be minimized by using specially engineered E. coli strains for expression. These strains have mutations in both the thioredoxin reductase (trxB) and glutathione reductase (gor) genes, and they greatly enhance folding of the scFvs in the E. coli cytoplasm 68 . Alternatively, scFvs expressed using the pComb3XSS vector can be extracted from the periplasmic space by removing the outer membrane of E. coli with osmotic shock buffer (0.5 M sucrose in PBS/Tris-buffered saline (TBS)). This generally yields a relatively pure preparation of scFvs. The purified scFvs should be stored in aliquots at −20 or −80 °C and repeated freezethaw cycles should be avoided. For better stability, we recommend storing purified scFvs at a concentration of 1 mg ml − 1 or higher. If obtaining a high concentration of scFvs is not possible, the protein can be concentrated or BSA (10 mg ml − 1 ) can be added before freezing.
Screening strategies based solely on the ability of an scFv to bind to the antigen would not provide information on the ability of that scFv to stabilize PTP1B-OX and inhibit its reactivation (Fig. 4) . To analyze systematically individual scFvs from enriched pools of phage particles after the in-solution panning, we used a phosphatase assay in solution (Box 2) to detect whether any scFvs inhibited the reactivation of oxidized PTP1B by the reducing agent (Fig. 4b,c) . Consequently, establishing conditions under which PTP1B is reversibly oxidized by H 2 O 2 in solution is of vital importance to screening for such scFvs (Fig. 4a) . It would be anticipated that conformation-sensor scFvs that recognize the oxidized form would not show direct inhibitory effects on the phosphatase activity of the active, reduced form of PTP1B. Therefore, it is an essential control to test this directly in assays of phosphatase activity. The scFvs can be further characterized by binding experiments with the reduced and oxidized form of the target protein. Such binding experiments can be performed by Ni-nitrilotriacetic acid (NTA) or hemagglutinin (HA) pull-down, exploiting the C-terminal 6His or HA tags in the scFvs, respectively, and by subsequent immunoblotting of the target protein (Fig. 4d) . It is also useful to determine Reversibly oxidized (1B-OX), reduced (1B-R) and mutant forms (1B-CASA) of PTP1B were incubated with purified scFv 26 , and the protein complex was captured using Ni-NTA agarose beads. The input, supernatant and eluate were separated by SDS-PAGE and PTP1B, and scFv in the complex was detected by immunoblotting with anti-PTP1B or anti-HA-HRP antibodies, respectively. • Autoclave the solution and store it at room temperature for several months.  crItIcal Dissolving PEG and NaCl into solution requires prolonged stirring. Ensure that the components are dissolved before autoclaving. Phosphatase assay buffer Phosphatase assay buffer contains 50 mM HEPES (pH 7.0), 100 mM NaCl and 0.1% BSA (wt/vol; with or without 5 mM TCEP). Dissolve 1.19 g of HEPES, 5.84 g of NaCl and 1 g of BSA in 900 ml of ddH 2 O. Adjust the pH to 7.0 and add water to bring the volume to 1 liter. Filter-sterilize the solution through a 0.2-µm filter unit and store it at 4 °C for several months. Add TCEP immediately before use. PMSF (100 mM in 100% isopropanol) Dissolve 0.87 g of PMSF in 50 ml of isopropanol. Store PMSF at − 20 °C for several months. ! cautIon PMSF is extremely toxic, and preparation of solutions should be done very carefully. Avoid contact with skin and eyes. Do not inhale.  crItIcal PMSF quickly degrades in aqueous solution at neutral pH. Add PMSF to the buffer immediately before use. RCML (20 mg ml − 1 in ddH 2 O) Dissolve 100 mg of RCML in 5 ml of ddH 2 O. Make 1-ml aliquots and store them at − 20 °C for several months. SDS sample loading buffer, 4× Mix 5 ml of 1 M Tris-HCl (pH 6.8), 4 g of SDS, 20 ml of 100% glycerol, 5 ml of 0.5 M EDTA, 40 mg of bromophenol blue and 13 ml of ddH 2 O and dissolve thoroughly. Store the SDS at − 20 °C for several years. Add DTT to a final concentration of 100 mM in the sample immediately before use. Super optimal broth (SOB) medium SOB medium contains 2% (wt/vol) tryptone, 0.5% (wt/vol) yeast extract, 10 mM NaCl, 2.5 mM KCl (pH 7.0), 10 mM MgCl 2 and 10 mM MgSO 4 . Add 20 g of tryptone, 5.0 g of yeast extract, 0.5 g of NaCl and 186 mg of KCl to 950 ml of ddH 2 O. Mix to dissolve and adjust the pH to 7.0 with NaOH. Adjust the volume to 980 ml with ddH 2 O and autoclave. Add 10 ml of 1 M MgCl 2 and 10 ml of 1 M MgSO 4 (both filter sterilized) and store the medium at room temperature for several months. Super optimal broth with catabolite repression (SOC) medium SOC contains 20 mM of glucose in SOB medium. Add 0.5 ml of 2 M glucose (filter-sterilized) to 50 ml of SOB and store it at 4 °C for several months. Buffers for biotinylated PTP1B purification Lysis buffer contains 25 mM Na 2 HPO 4 (pH 6.5), 10 mM NaCl, 1 mM EDTA, 5 mM DTT, 1 mM PMSF, 2 mM benzamidine, 1 complete protease inhibitor tablet per 50 ml and 0.5 mg ml − 1 lysozyme; Biotin blocking and elution buffer contains 2 mM d-biotin in PBS; Biotin elution buffer contains 5 mM d-biotin in PBS; Mono-Q buffer A (Q-Buffer A) contains 25 mM Tris-HCl (pH 7.5), 1 mM EDTA and 5 mM DTT; Mono-Q Buffer B (Q-Buffer B) contains 25 mM Tris-HCl (pH 7.5), 1 M NaCl, 1 mM EDTA and 5 mM DTT; and PTP1B storage buffer contains 25 mM Tris-HCl (pH 7.0), 50 mM NaCl, 5 mM DTT, 0.1 mM PMSF (add before freezing the protein), 0.02% (wt/vol) NaN 3 and 50% (vol/vol) glycerol. These buffers, without the additives (PMSF, benzamidine, protease inhibitor, lysozyme, d-biotin, DTT), are stored at 4 °C for months. Buffers for scFv purification Lysis buffer contains 50 mM Na 2 HPO 4 (pH 8.0), 500 mM NaCl, 10 mM imidazole, 1 mM PMSF and complete EDTA-free protease inhibitor cocktail; washing buffer contains 50 mM Na 2 HPO 4 (pH 8.0), 500 mM NaCl and 20 mM imidazole; and elution buffer contains 50 mM Na 2 HPO 4 (pH 8.0), 500 mM NaCl and 250 mM imidazole. These buffers, without the additives (PMSF and protease inhibitor), are stored at 4 °C for months. proceDure selection of specific scFvs by in-solution panning • tImIng ~3 d per panning cycle 1| Prewash streptavidin-coated magnetic beads with 10 volumes of TBS containing 2% (wt/vol) BSA and 0.02% (wt/vol) NaN 3 by mixing and centrifuging at room temperature at 12,000g for 30 s. Resuspend the washed beads in TBS containing 2% (wt/vol) BSA, 5 mM DTT and 0.02% (wt/vol) NaN 3 , to adjust the final streptavidin concentration to 10 mg ml − 1 .  crItIcal step The binding capacity of the beads is 5-10 µg (30-60 pmol) of biotinylated antibody (IgG) per mg of streptavidin beads. Therefore, 25 µl of streptavidin beads at a concentration of 10 mg ml − 1 should bind 7.5-15.0 pmol of biotinylated protein.
2| Preadsorb the scFv library with streptavidin beads in a final volume of 400 µl in a 1.5-ml microcentrifuge tube: mix 2 × 10 12 phage particles in 400 µl of 2% (wt/vol) BSA in TBS plus 1% (vol/vol) Tween-20 and 10 mM DTT, and then add 25 µl of prewashed streptavidin beads and incubate for 2 h at 4 °C.
3|
Add recombinant 37-kDa wild-type PTP1B (4 µg) in 400 µl of 1× TBS, 2% (wt/vol) BSA, 0.5% (vol/vol) Tween-20 and 5 mM DTT to 200 µl of preadsorbed phage particles (10 12 phage particles) and incubate the mixture for 4 h at 4 °C.  crItIcal step In the second panning step, use 10 µg (25-fold molar access) of untagged wild-type PTP1B (PTP1B-WT), instead of the 4 µg (10-fold molar access) used in the first round of panning. In the subsequent rounds of panning, use 20 µg of untagged wild-type PTP1B, which is a 50-fold molar excess of the biotinylated PTP1B-CASA.
4|
Add the biotinylated PTP1B-CASA (400 ng) in 400 µl of 1× TBS, 2% (wt/vol) BSA, 0.5% (vol/vol) Tween-20 and 5 mM DTT to this mixture and incubate it at 4 °C for 4 h in a humidified box.
5|
Add prewashed streptavidin beads (25 µl) to the phage/antigen mixture in the tube and incubate it for 15 min at room temperature on a rocking platform.
6| Add 100 µl of 1 mM biotin (~0.1 mM final) in TBS containing 2% (wt/vol) BSA and 5 mM DTT to the solution and incubate it for 5 min at room temperature to block the remaining streptavidin-binding sites on the beads.  crItIcal step This step is important in reducing the number of nonspecific, bead-binding scFvs during the panning steps. Biotin at this concentration does not compete with the biotin-streptavidin interaction, and the scFv-antigen will be captured efficiently with a net reduction of nonspecific scFvs. ? trouBlesHootIng 7| Aspirate the supernatant after the incubation and wash the beads three times by resuspending them in 1 ml of TBS and centrifuging at room temperature for 1 min at 12,000g.
8|
Elute the phage particles associated with the streptavidin-biotinylated PTP1B-CASA complex by incubating them with 100 µl of elution buffer (0.2 M glycine-HCl (pH 2.2), 1 mg ml − 1 BSA) for 10 min at room temperature, with occasional pipetting up and down to mix the beads.
9|
Hold the beads at the bottom of the tube with the magnet. Collect the supernatant and transfer it to a new microcentrifuge tube; neutralize the supernatant with 20 µl of neutralization buffer (1 M Tris base (pH 9.1)).
10|
Add the eluate to infect a 2-ml overnight culture of XL-1 Blue strain of E. coli in SB medium and incubate it at room temperature for 15 min.
11| Add 6 ml of prewarmed (at 37 °C) SB medium (with 1.6 µl of 100 mg ml − 1 carbenicillin and 12 µl of 5 mg ml − 1 tetracycline) and transfer the culture to a 50-ml tube; shake the tube at 37 °C, 250 r.p.m. for 1 h. 12| Add 2.4 µl of 100 mg ml − 1 carbenicillin to the culture and shake it for an additional hour at 250 r.p.m. and 37 °C.
13|
Titer the input and output phage to estimate the number of phage particles before and after each panning step. Dilute 5 µl of the infected culture in 500 µl of SB medium and plate 10 µl and 100 µl of this dilution on LB-ampicillin or LB-carbenicillin plates for output titration. Infect 100 µl of E. coli culture with 2 µl of a 10 − 8 dilution of the phage preparation in SB. Incubate the infected culture for 15 min at room temperature and plate it on an LB-ampicillin plate. Incubate the output and input plates at 37 °C overnight. ? trouBlesHootIng 14| Add the helper phage VCSM13 (10 12 plaque-forming units (p.f.u.)) to the 8-ml culture (from Step 12) and transfer it to a 500-ml flask. Add 91 ml of prewarmed (37 °C) SB medium (with 46 µl of 100 mg ml − 1 carbenicillin and 184 µl of 5 mg ml − 1 tetracycline) and shake the culture at 300 r.p.m. for 2 h at 37 °C.
15|
Add 140 µl of 50 mg ml − 1 kanamycin and continue shaking the culture overnight at 300 r.p.m. and 37 °C.
16|
Centrifuge the culture at 3,000g for 15 min at 4 °C.
17|
Transfer the supernatant to a clean 250-ml centrifuge bottle and add 25 ml of 5× PEG/NaCl (final concentration 4% (wt/vol) PEG, 0.5 M NaCl). Mix and incubate the mixture on ice for 30 min.
18| Precipitate the phage particles by centrifuging them at 15,000g for 15 min at 4 °C.
19|
Drain the supernatant and resuspend the phage particles in 2 ml of 1% (wt/vol) BSA in TBS. Filter the phage preparation using 0.20-µm disc filters. ? trouBlesHootIng  pause poInt Phage preparations can be stored at 4 °C for several weeks.
20|
Carry out another round of panning by repeating Steps 1-19 using the amplified phage particles. Perform a total of five rounds of panning before proceeding to the next step.
21|
Determine the input and output phage titers on LB-carbenicillin plates before and after each round of panning. Use these output titer plates in Step 21 as the source of individual phage particles expressing scFvs fused to the surface protein pIII. 
25|
Dilute this overnight culture to 1:50 in SB medium and incubate at 37 °C at 250 r.p.m. until the OD 600 becomes ~0.8.
26| Shake this culture slowly at 100 r.p.m. for 15 min at 37 °C to regenerate the sheared F′ pili of the TOP10F′ strain.
27|
Infect these TOP10F′ cells with phage particles expressing individual scFvs (from Step 23, one representative scFv from each sorted group) by adding ~10 12 phage particles per ml of bacterial cultures and incubating at room temperature for 15 min with occasional gentle shaking.  crItIcal step The use of TOP10F′ cells is essential for the expression and purification of scFvs without pIII fusion. TOP10F′ is a nonsuppressor E. coli strain that reads the amber codon as the stop codon, and an scFv is produced without being fused to the pIII surface protein of the phage.
28| Dilute the infected culture 1:50 in SB medium with 50 µg ml − 1 of carbenicillin and incubate at 37 °C and 250 r.p.m. until the optical density at 600 nm (OD 600 ) reaches 0.5. 
31|
Sonicate the cells on ice three times for 15 s with 1-min intervals in between (pulsing at 100% duty cycle, output control set at 5) and then once for 180 s (pulsing at 50% duty cycle, output control set at 5). Centrifuge at 50,000g for 30 min at 4 °C.
32|
Purify the soluble scFvs from the supernatant using Ni-NTA agarose gravity columns. Add the supernatant to the column and wash it with 20 column-volumes of wash buffer. ? trouBlesHootIng 33| Elute the bound protein with the elution buffer. Measure the concentration of the purified scFvs by Bradford protein assay. reversible oxidation and inactivation of ptp1B by H 2 o 2 • tImIng 1 d 34| Mix purified PTP1B(1-321; see Reagents) at a concentration of 15 nM with increasing concentrations of H 2 O 2 (0.05-100 mM) in phosphatase assay buffer and incubate at room temperature for 10 min.  crItIcal step It is important to determine the optimal conditions and concentration of H 2 O 2 for reversible oxidation and inactivation of PTP1B. The conformation-specific scFvs inhibit the phosphatase activity of PTP1B by stabilizing its oxidized inactive form and preventing the reactivation of the enzyme by reducing agent.
35|
Equilibrate a Zeba desalting column (0.5 ml) by washing it three times with phosphatase assay buffer without any reducing agent. Apply 125 µl of the oxidized PTP1B to the column and collect the eluate as the sample from which H 2 O 2 is removed.
36|
Measure the phosphatase activity for each protein sample treated with different H 2 O 2 concentrations using 32 P-labeled RCML as the substrate, with or without 5 mM TCEP (Box 2). ? trouBlesHootIng 37| Compare the activity of each sample with that of the untreated PTP1B in the presence of 5 mM TCEP.
screening for conformation-sensor scFvs • tImIng ~2 d 38| Oxidize and transiently inactivate recombinant PTP1B with H 2 O 2 , so that the phosphatase activity can be completely restored after the removal of H 2 O 2 by quick buffer exchange and the addition of a reducing agent (TCEP), using the optimized conditions determined in Steps 34-37. After H 2 O 2 treatment and removal, incubate the PTP1B with purified, bacterially expressed scFvs in 100-fold molar excess. Measure phosphatase activity under reducing conditions (Box 2) to assess the potential of individual scFvs to stabilize the reversibly oxidized conformation.
39|
Incubate the purified scFv (750 nM) with PTP1B (7.5 nM) under reducing conditions (5 mM TCEP) in 50 mM HEPES (pH 7.0), 100 mM NaCl and 0.1% (wt/vol) BSA for 30 min at room temperature, to assess whether the scFv exerts any direct inhibitory influence on phosphatase activity of the reduced from of PTP1B.
40|
Determine the phosphatase activity in these protein mixtures from Step 39 by assay with 32 P-labeled RCML as substrate (Box 2).
41|
Incubate reversibly oxidized PTP1B (7.5 nM) (as prepared in Steps 34-37) with individual scFvs (750 nM) for 30 min at room temperature in the same binding conditions (as in Step 39) , except in the absence of the reducing agent (TCEP), in order to determine the effect of scFv binding on the reduction and reactivation of PTP1B-OX.
42|
Determine PTP1B activity in each sample using 100 nM 32 P-RCML as the substrate, with or without 5 mM TCEP as the reducing agent (Box 2). ni-nta pull-down experiments • tImIng 3 d 43| Oxidize purified PTP1B (50 nM) with 250 µM H 2 O 2 , followed by a quick buffer exchange to remove H 2 O 2 (Steps 33-36).
44| Incubate purified scFvs in a 100-fold molar excess of PTP1B-OX or PTP1B-CASA or with PTP1B under reducing conditions (with 2 mM TCEP) in binding buffer for 2 h at 4 °C.
45|
Add Ni-NTA agarose (50 µl as a 50% (vol/vol) slurry equilibrated in the binding buffer) and incubate for 1 h at 4 °C. Alternatively, perform a similar experiment using anti-HA high-affinity antibody (clone 3F10) coupled to agarose beads (50 µl as a 50% (vol/vol) slurry) to capture the scFv-PTP1B-OX complex from solution.
46|
Pull down the protein complex bound to Ni-NTA/anti-HA agarose beads and wash it (three times, 5 min each, at 4 °C) with binding buffer containing 20 mM imidazole.
47|
Elute the protein complex from the Ni-NTA agarose beads with 500 mM imidazole (in binding buffer) for 15 min at 4 °C with gentle shaking. For anti-HA agarose beads, add 50 µl of 2× sample loading buffer and boil the sample for 5 min at 100 °C. is preserved before the panning and enhances selection of scFv clones that would bind to different epitopes of the target antigen. An increased phage output/input ratio after each round of panning generally indicates enrichment of specific scFvs. By using this protocol, we observed an ~1,000-fold enrichment of the scFvs after the fourth round of panning (Fig. 3b) . With an input of 10 11 -10 12 phage particles, the expected output titer after the first and second round of selection is generally in the range of 10 5 -10 7 phage particles. After the third and fourth round of panning, this number is expected to increase to 10 7 -10 9 . If the phage titer falls out of this range, the selection procedure should be optimized. Generally, if an excessive number of panning steps are performed (more than five rounds), dominant and potentially unwanted clones may emerge. The average scFv insert length is ~700 bp, encoding the conserved framework region and variable CDRs. We sequenced ~400 randomly selected scFv clones after different panning steps using phagemid-specific primers. In our case, 95% of the sequences were full-length, functional scFvs, indicating that the cloning strategy and library display worked appropriately. In cases in which scFvs are found with frequent incomplete sequences, immature stop codons before the C-terminal 6His or HA tags or no scFv inserts at all, the library should be reconstructed. Sequences should be sorted into groups on the basis of differences in their hypervariable regions. Selection of functional scFv sequences can be confirmed by checking that the sequences are from the animal that was immunized to generate the library. All the selected sequences in our case aligned with the amino acid sequence of light and heavy chains of chicken IgG, except for the differences in the hypervariable regions. The most variable segment in the scFvs is expected to be in the CDR3 region of the heavy chain. The selected scFv sequences should also contain the 6-His and HA tags at the C terminus, the presence of which in frame with the scFv sequence is an indication that the library cloning and ligation worked. It is advisable to check for clonal diversity after the second and subsequent rounds of panning. On using our protocol, we found diversity among the functional scFv sequences to be ~70% after the second round and ~20% after the fourth round of panning (Fig. 3c) . selection of candidate scFvs by in vitro screening. When using this protocol, positive clones are expected after as few as two rounds of selection. This outcome may vary depending on the antigen quality and property, binding conditions, blocking strategy, washing stringency, and elution conditions. For rapid screening, we expressed individual scFvs from enriched library in E. coli using the phagemid vector (pComb3XSS) that was used for constructing the library. Purification of soluble scFv from a small-scale culture (10 ml) is expected to yield 0.01-0.1 mg of purified scFv with 50-75% purity as assessed by SDS-PAGE. If desirable purity of the scFv is not achieved from the bacterial lysates, it can be isolated from periplasmic fractions.
When incubated with reversibly oxidized PTP1B, the candidate scFvs are expected to demonstrate substantial inhibition (50%) of reactivation (Fig. 4c) . None of the selected scFvs should have a direct inhibitory effect on the phosphatase activity of PTP1B under reducing conditions. Initially, we performed the screening for specific scFvs from the fourth and fifth round of panning; however, candidates could be isolated as early as the second round of panning. In fact, some of the clones that we found after the fourth round of panning were also identified after the second round. This indicates that the enrichment and selection criteria in this protocol are sufficient for the isolation of specific binders from as early as the second round of panning.
The scFvs that are selected by the primary screening are expected to bind the oxidized protein but not the reduced active enzyme. As a control, we also tested binding with PTP1B-CASA, and observed that scFvs specific to PTP1B-OX should bind to the mutant protein, which is structurally identical to the oxidized enzyme (Fig. 4d) . In similar binding experiments, scFvs that did not stabilize the inactive conformation in the enzymatic screening assay should not bind to the oxidized enzyme. In addition, one can also determine the binding constants of individual scFvs by using interaction analysis techniques such as surface plasmon resonance. Typically, scFvs isolated from an immune library against human antigens have affinities in the nanomolar range. specificity of the scFvs. The closest relative of PTP1B in the PTP family is TCPTP, which has 75% sequence identity within the catalytic domain 33 . This approach for generating conformation-specific antibodies to PTP1B-OX generated scFvs with remarkable selectivity that could distinguish between these two closely related enzymes. Currently, there is no crystal structure of oxidized TCPTP; however, overlap of the crystal structure of the active, reduced form of these two closely related PTPs illustrated some structural differences. Conformational changes associated with oxidation are also likely to reveal additional structural attributes that contribute to this specificity. The use of the entire catalytic domain of PTP1B-OX as the antigen to construct the scFv library and for subsequent screening is likely to be important. We do not anticipate that this selectivity would have been achieved if the scFvs were generated and screened for using the oxidized peptide of the active site catalytic motif, which is well conserved in the PTP family. competIng FInancIal Interests The authors declare no competing financial interests.
